Mediwound Ltd.
|
|||
Date: August 14, 2019
|
By:
|
/s/ Sharon Malka | |
Name: Sharon Malka | |||
Title: Chief Executive Officer |
(1) |
To approve an updated compensation policy for the executive officers and directors of our Company, or the Compensation Policy, in accordance with the requirements
of the Israeli Companies Law, 5759-1999, or the Companies Law; and
|
(2) |
To approve an amendment to Article 6 of our Company’s Articles of Association, as amended, that increases our authorized share capital from 372,445.08 New Israeli
Shekels, or NIS, divided into 37,244,508 ordinary shares, par value NIS 0.01 each, to NIS 500,000 divided into fifty million (50,000,000) ordinary shares, par value NIS 0.01 each.
|
|
Sincerely,
Mr. Stephen T. Wills
Active Chairman of the Board of Directors
|
(1) |
Approval of an updated compensation policy for the executive officers and directors of our Company (the “Compensation Policy”), in accordance with the requirements of the Israeli Companies Law, 5759-1999, (the “Companies Law”); and
|
(2) |
Approval of an amendment to Article 6 of our Company’s Articles of Association, as amended (the “Articles”) that increases our authorized share capital from 372,445.08 New Israeli Shekels (“NIS”),
divided into 37,244,508 ordinary shares, par value NIS 0.01 each, to NIS 500,000.00 divided into fifty million (50,000,000) ordinary shares, par value NIS 0.01 each.
|
• |
the majority voted in favor of the proposal includes a majority of the shares held by shareholders who are neither controlling shareholders nor in possession of
a conflict of interest (referred to under the Companies Law as a “personal interest”) in the approval of the updated Compensation Policy that are voted at the Meeting, excluding abstentions; or
|
• |
the total number of shares held by non-controlling, non-conflicted shareholders (as described in the previous bullet-point) voted against the proposal does not
exceed 2% of the aggregate voting power in the Company.
|
Name
|
Number of Ordinary Shares
Beneficially Owned (1) |
Percentage of Ownership (2)
|
||||||
Clal Biotechnology Industries Ltd. (3)
|
9,429,555
|
34.7
|
%
|
|||||
Wellington Management Group LLP (4)
|
3,432,542
|
12.6
|
%
|
|||||
Lior Rosenberg (5)
|
1,945,322
|
7.1
|
%
|
|||||
Migdal Insurance & Financial Holdings Ltd. (6)
|
2,126,058
|
7.8
|
%
|
|||||
Yelin Lapidot Mutual Funds Management Ltd. (7)
|
1,703,081
|
6.3
|
%
|
|||||
Directors and executive officers as a group (8)
|
2,520,748
|
8.9
|
%
|
(1)
|
Beneficial ownership is determined in accordance with the rules of the U.S. Securities and Exchange Commission (the “SEC”), and generally includes voting or investment power with respect to securities. Ordinary shares relating to options currently
exercisable or exercisable within 60 days of the date of this table are deemed outstanding for computing the percentage of the person holding such securities but are not deemed outstanding for computing the percentage of any other person.
Except as indicated by footnote, and subject to community property laws where applicable, the persons named in the table above have sole voting and investment power with respect to all shares shown as beneficially owned by them.
|
(2)
|
The percentages shown are based on 27,178,839 ordinary shares that are issued and outstanding as of August 14, 2019.
|
(3)
|
As reported in a Schedule 13G/A filed on February 12, 2019, shares beneficially owned consist of: (i) 8,208,973
ordinary shares held by Clal Life Sciences, LP, an Israeli limited partnership, whose managing partner is Clal Application Center Ltd., a wholly owned subsidiary of Clal Biotechnology Industries Ltd. (“CBI”); and (ii) 1,220,582 ordinary shares held by CBI. As reported on a Schedule 13G/A filed on February 14, 2019 by Access Industries Holdings LLC,
Access Industries Holdings LLC indirectly owns 100% of the outstanding shares of Clal Industries Ltd., which owns the majority of the outstanding shares of, and controls, CBI. The address of Clal Industries Ltd. is the Triangular
Tower, 3 Azrieli Center, Tel Aviv 67023, Israel and the address of Access Industries Holdings LLC is c/o Access Industries Group, 730 Fifth Avenue, New York, New York 10019, United States.
|
(4)
|
As reported in a Schedule 13G/A filed on February 12, 2019, shares beneficially owned consist of 3,432,542
ordinary shares owned of record by clients of one or more investment advisers directly or indirectly owned by Wellington Management Group LLP. Of the 3,432,542 shares beneficially owned, Wellington Management Group LLP has
shared voting power with respect to 3,128,149 ordinary shares and shared dispositive power with respect to all 3,432,542 ordinary shares;
Wellington Group Holdings LLP has shared voting power with respect to 3,128,149 ordinary shares and shared dispositive power with respect to
all 3,432,542 ordinary shares; Wellington Investment Advisors Holdings LLP has shared voting power with respect to 3,128,149 ordinary shares
and shared dispositive power with respect to all 3,432,542 ordinary shares; and Wellington Management Company LLP has shared voting power with respect to 3,128,149 ordinary shares and shared dispositive power with respect to 3,326,736 ordinary shares. The address of Wellington Management Group is c/o Wellington Management Company LLP, 280 Congress Street, Boston,
MA 02210.
|
(5)
|
As reported in a Schedule 13G/A filed on February 6, 2019, shares beneficially owned consist of: (i) 140,367
ordinary shares held directly by Prof. Rosenberg; (ii) 94,750 ordinary shares issuable upon exercise of outstanding options held directly by Prof. Rosenberg that are currently exercisable or exercisable within 60 days of
December 31, 2018; and (iii) 1,710,205 ordinary shares held by L.R. Research and Development Ltd. in trust for the benefit of Prof. Rosenberg. Prof. Rosenberg is the sole shareholder of L.R. Research and Development Ltd.
|
(6)
|
As reported in a Schedule 13G filed on February 14, 2019, shares beneficially owned consist of: (i) 1,909,112
ordinary shares held for members of the public through, among others, provident funds, mutual funds, pension funds and insurance policies, which are managed by subsidiaries of Migdal Insurance & Financial Holdings Ltd (“Migdal”), each of which makes independent voting and investment decisions, and (ii) 216,946 ordinary shares held for Migdal’s
own account (Nostro account). Migdal is a widely held public company listed on the Tel Aviv Stock Exchange. The address of Migdal is 4 Efal Street, Petah Tikva 49512, Israel.
|
(7)
|
As reported in a Schedule 13G/A filed on February 11, 2019, shares beneficially owned consist of: (i)
1,432,081 ordinary shares owned of record by Yelin Lapidot Mutual Funds Management Ltd., a wholly‑owned subsidiary of Yelin Lapidot
Holdings Management Ltd. (“Yelin Lapidot Holdings”), for the benefit of the members of the mutual funds; plus (ii) 280,000 ordinary shares owned of record by provident funds managed by Yelin Lapidot Provident Funds Management Ltd., which is also a wholly‑owned subsidiary of Yelin Lapidot Holdings. Yelin Lapidot Holdings, Dov Yelin and Yair Lapidot each share voting and dispositive power with
respect to all 1,703,081 shares. Dov Yelin and Yair Lapidot each own 24.38% of the share capital and 25% of the voting rights of Yelin Lapidot Holdings, and are responsible for the day-to-day management of Yelin Lapidot
Holdings. Each of Yelin Lapidot Mutual Funds Management Ltd. and Yelin Lapidot Provident Funds Management Ltd. operates under
independent management and makes its own independent voting and investment decisions. The address of Yelin Lapidot Holdings is 50 Dizengoff St., Dizengoff Center, Gate 3, Top Tower, 13th floor, Tel Aviv 64332, Israel.
|
(7)
|
As reported in a Schedule 13G/A filed on February 11, 2019, shares beneficially owned consist of: (i)
1,432,081 ordinary shares owned of record by Yelin Lapidot Mutual Funds Management Ltd., a wholly‑owned subsidiary of Yelin Lapidot
Holdings Management Ltd. (“Yelin Lapidot Holdings”), for the benefit of the members of the mutual funds; plus (ii) 280,000 ordinary shares owned of record by provident funds managed by Yelin Lapidot Provident Funds Management Ltd., which is also a wholly‑owned subsidiary of Yelin Lapidot Holdings. Yelin Lapidot Holdings, Dov Yelin and Yair Lapidot each share voting and dispositive power with
respect to all 1,703,081 shares. Dov Yelin and Yair Lapidot each own 24.38% of the share capital and 25% of the voting rights of Yelin Lapidot Holdings, and are responsible for the day-to-day management of Yelin Lapidot
Holdings. Each of Yelin Lapidot Mutual Funds Management Ltd. and Yelin Lapidot Provident Funds Management Ltd. operates under
independent management and makes its own independent voting and investment decisions. The address of Yelin Lapidot Holdings is 50 Dizengoff St., Dizengoff Center, Gate 3, Top Tower, 13th floor, Tel Aviv 64332, Israel.
|
(8)
|
Consists of (i) 1,855,729 ordinary shares held directly or indirectly by the Company’s directors and executive officers;
and (ii) 665,019 ordinary shares underlying outstanding options granted to the executive officers and directors which will have vested within 60 days of August 14, 2019 (i.e., on or prior to October 13, 2019).
|
◾ |
The updated Compensation Policy slightly raises the limit for the non-material portion of an annual bonus that may be paid to the Company’s Chief Executive
Officer (“CEO”) based on a discretionary evaluation of his overall performance by the compensation committee and the Board—from 20%
to 25% -- but adds that such discretionary evaluation of the CEO’s
overall performance by the compensation committee and the Board will be based on quantitative and qualitative criteria. [Section 9.3]
|
◾ |
The updated Compensation Policy sets a more demanding vesting schedule in a default scenario (unless otherwise determined for a particular grant) for
equity-based awards to executive officers based on a four-year vesting schedule (25% vests at the end of one year, and an additional 6.25% vests at the end of each subsequent quarter over the following three years). This vesting
schedule is in line with our 2014 Equity Incentive Plan. Under our existing Compensation Policy, the guidelines were more general (minimum two-year vesting period, with a minimum one-year period prior to the vesting of the first
tranche). [Section 12.3]
|
◾ |
The updated Compensation Policy revises the framework for our current and future directors & officers (including any directors or executive officers who are
affiliated with a controlling shareholder of our Company) liability (D&O) insurance coverage, raising the coverage limit up to $40 million from up to $30 million (including under a Side A DIC (Difference in Conditions) policy),
while changing the maximum annual premium that we may pay from a maximum of a 30% increase from the previous year’s premium, to an absolute ceiling equal to 2% of the coverage of the policy. The updated Compensation Policy furthermore
provides details as to the permitted range of coverage and premiums for D&O insurance that we may purchase in special circumstances (including for a public offering, or for a “run off” policy following a change of control).
[Section 19]
|
◾ |
The updated Compensation Policy provides explicitly that any directors or executive officers who are affiliated with a controlling shareholder of our Company
may be entitled to exculpation and indemnification (in addition to D&O insurance coverage). Until now, any directors or executive officers who have been affiliated with a controlling shareholder of our Company have been granted
exculpation and indemnification after we obtained a specific approval from the required corporate organs of our Company (including our shareholders). [Sections 18 and 19.1]
|
◾ |
The updated Compensation Policy explicitly “hard wires” in the terms of annual cash fees for non-employee directors, setting a maximum of $150,000 per year,
plus value-added tax (VAT), subject to an allowance to deviate from that limit in the case of a professional director, expert director or a director who makes a unique contribution to our Company. Our existing Compensation Policy
generically provides for periodic and per-meeting fees without providing details. Both our existing and our updated Compensation Policy generally provide that external directors will be paid in accordance with the “external director”
compensation regulations under the Companies Law. [Section 20]
|
Yavne, Israel
August 14, 2019
|
By order of the Board of Directors:
Mr. Stephen T. Wills
Active Chairman of the Board of Directors
|
1. |
Introduction
|
• |
interpret the Policy;
|
• |
prescribe, amend and rescind rules and regulations relating to and for carrying out the Policy, as it may deem appropriate; and
|
• |
determine any other matter which is necessary or desirable for, or incidental to, the administration of the Policy and any determination made pursuant thereto.
|
2. |
Objectives
|
2.1. |
To closely align the interests of the Executive Officers with those of MediWound’s shareholders in order to enhance shareholder value;
|
2.2. |
To align a significant portion of the Executive Officers’ compensation with
MediWound’s short and long-term goals and performance;
|
2.3. |
To provide the Executive Officers with a structured compensation package, including competitive salaries, performance-motivating cash and equity incentive
programs and benefits, and to be able to present to each Executive Officer an opportunity to advance in a growing organization;
|
2.4. |
To strengthen the retention and the motivation of Executive Officers in the long term;
|
2.5. |
To provide appropriate awards in order to incentivize superior individual excellency and corporate performance; and
|
2.6. |
To maintain consistency in the way Executive Officers are compensated.
|
3. |
Compensation Instruments
|
3.1. |
Base salary (as described in Section 6 below);
|
3.2. |
Benefits (including any of the benefits described in Section 7 below);
|
3.3. |
Cash bonuses (including any bonuses described in Sections 8 through 10 below);
|
3.4. |
Equity-based compensation (as described in Sections 12 and 13 below);
|
3.5. |
Retirement and termination terms (as described in Sections 14 through 16 below);
|
3.6. |
Exculpation, indemnification and insurance (as described in Sections 18 and 19 below); and
|
4. |
Overall Compensation - Ratio Between Fixed and Variable Compensation
|
4.1. |
This Policy aims to balance the mix of “Fixed Compensation” (comprised of base salary and benefits) and “Variable Compensation” (comprised of annual cash bonuses and equity-based compensation, which equity-based
compensation shall be valued based on the fair value thereof on the date of grant, to be apportioned over the vesting period on a linear basis) in an Executive Officer’s total compensation package in a given fiscal year. The balance
between Fixed Compensation and Variable Compensation is meant to, among other things, appropriately incentivize Executive Officers to meet MediWound’s
short-term and long-term goals while taking into consideration the Company’s need to manage a variety of business risks.
|
4.2. |
The total Variable Compensation of each Director or Executive Officer shall not
exceed 67% of the total compensation package (i.e., the total of Variable Compensation plus Fixed Compensation) of such Executive Officer on an annual basis. For the sake of clarity, for purposes of determining the total
compensation package in a given fiscal year, additional compensation elements, such as other (non-annual) bonuses under Section 10, adjustment-period compensation and/or retirement bonuses, granted in accordance with Sections 14 and
15 below, and the value of D&O liability insurance coverage (provided pursuant to Section 19 below), shall be excluded from both Variable Compensation
and Fixed Compensation.
|
4.3. |
It should be clarified that the Fixed Compensation may constitute 100% of the total compensation package for an Executive Officer in any year (under
circumstances in which a variable component will not be approved for that year and/or in the event of a failure to meet the set goals, if and when determined).
|
5. |
Intra-Company Compensation Ratio
|
5.1. |
In the process of drafting and updating this Policy, MediWound’s Board and Compensation Committee have examined the ratio between employer cost associated with
the engagement of the Executive Officers, including directors, and the average and median employer cost associated with the engagement of MediWound’s other employees (including contractor employees as defined in the Companies Law)
(the “Ratio”).
|
5.2. |
The possible ramifications of the Ratio on the daily working environment in MediWound were examined and will continue to be examined by MediWound from time to
time in order to ensure that levels of executive compensation, as compared to the overall workforce will not have a negative impact on work relations in MediWound.
|
6. |
Base Salary
|
6.1. |
A base salary provides stable compensation to Executive Officers and allows MediWound to attract and retain competent executive talent and maintain a stable
management team. The base salary varies among Executive Officers, and is individually determined according to the educational
background, prior vocational experience, qualifications, role at the Company, business responsibilities and the past performance of each Executive Officer.
|
6.2. |
Since a competitive base salary is essential to MediWound’s ability to attract and retain highly skilled professionals, MediWound will seek to establish a base
salary that is competitive with base salaries paid to Executive Officers in other companies operating in MediWound’s industry that are similar in their characteristics to MediWound, as much as possible, while considering, among other
factors, such companies’ size and characteristics including their revenues, profitability rate, growth rates, market capitalization, number of employees and operating arena (in Israel or globally). To that end, MediWound shall utilize
as a reference, comparative market data and practices, which may include, among other tools, a compensation survey that compares and analyzes the level of the overall compensation package offered to an Executive Officer of the Company
with compensation packages of officers at other companies who are in similar positions to that of the relevant officer. Such compensation survey may be conducted internally or through an external independent consultant.
|
6.3. |
The Compensation Committee and the Board may periodically consider and approve base
salary adjustments for Executive Officers. The main considerations for salary adjustment are similar to those used in initially determining the base salary, but may also include change of role or responsibilities, recognition for
professional achievements, regulatory or contractual requirements, budgetary constraints or market trends. The Compensation Committee and the Board will also consider the previous and existing compensation arrangements of the
Executive Officer whose base salary is being considered for adjustment. When determining the base salary, the Company may also decide to consider, at the sole discretion of the Compensation Committee and the Board and as
required, the prevailing pay levels in the relevant market, the base salary and total compensation package of comparable Executive Officers in the Company, the ratio between the Executive Officer’s compensation package and the
salaries of other employees in the Company and specifically the median and average salaries, and the effect that such ratio may have on work relations in the Company.
|
7. |
Benefits
|
7.1. |
The following benefits may be granted to the Executive Officers in order, among other things, to comply with legal requirements. It shall be clarified that the
list below is an open list and MediWound (subject to the applicable required approvals) may grant to its Executive Officers other similar, comparable or customary benefits, subject to applicable law and to MediWound’s policies and
procedures:
|
7.1.1. |
Vacation days in accordance with market practice;
|
7.1.2. |
Sick days in accordance with market practice;
|
7.1.3. |
Convalescence pay according to applicable law;
|
7.1.4. |
Monthly remuneration for a study fund, as allowed by applicable law and with reference to MediWound’s practice and the common market practice (including
contributions on bonus payments);
|
7.1.5. |
Medical insurance, in accordance with market practice and applicable law;
|
7.1.6. |
Contribution on behalf of the Executive Officer to an insurance policy or a pension fund, as allowed by applicable law and with reference to MediWound’s
policies and procedures and the common market practice (including contributions on bonus payments);
|
7.1.7. |
Contribution on behalf of the Executive Officer towards work disability insurance, as allowed by applicable law and with reference to MediWound’s policies and
procedures and to the common market practice.
|
7.1.8. |
Periodic medical examination;
|
7.1.9. |
Leased car or company car (as well as bearing the cost of related expenses or reimbursement thereof), or the value of the use thereof, or transportation
allowance;
|
7.1.10. |
Travel benefits, including travel insurance;
|
7.1.11. |
Telecommunication and electronic devices and communication expenses, including cellular telephone and other devices, personal computer/laptop, internet,
etc. or the value of the use thereof;
|
7.1.12. |
Paid vacation, including, if applicable, the redemption thereof;
|
7.1.13. |
Sick days;
|
7.1.14. |
Holiday and special occasion gifts;
|
7.1.15. |
Recuperation pay;
|
7.1.16. |
Expense reimbursement, including reimbursement of business travel
(including a daily stipend when traveling) and other business related expenses;
|
7.1.17. |
COBRA (for US employees);
|
7.1.18. |
Leased car or company car (as well as bearing the cost of related expenses or reimbursement thereof), or the value of the use thereof, or
transportation allowance;
|
7.1.19. |
Change-of-control provisions;
|
7.1.20. |
Loans or advances (to the extent permitted under applicable law);
|
7.1.21. |
Professional or academic courses or studies;
|
7.1.22. |
Newspaper or online subscriptions;
|
7.1.23. |
Professional membership dues or subscription fees;
|
7.1.24. |
Professional advice or analysis (such as pension, insurance and tax);
|
7.1.25. |
Expense coverage for relocation or repatriation to another geography, as well as similar, comparable or customary benefits
as applicable in the relevant jurisdiction in which he or she is employed or additional payments to reflect adjustments in cost of living due to relocation/repatriation, such as reimbursement for
out of pocket, one-time payments, and other ongoing expenses, such as housing allowance, car allowance, and home leave visit;
|
7.1.26. |
Other benefits generally provided to Company employees (or any applicable affiliate or division); and
|
7.1.27. |
Other benefits or entitlements mandated by applicable law.
|
7.2. |
The benefits that may be provided to Executive Officers under Sections 7.1.26 and 7.1.27 above shall be determined based on the relevant jurisdiction in which
an Executive Officer is employed and the methods described in Section 7.2 of this Policy (with the necessary changes and adjustments).
|
8. |
Annual Cash Bonuses - The Objective
|
8.1. |
Compensation in the form of an annual cash bonus is an important element in aligning the Executive Officers’ compensation with MediWound’s objectives and
business goals. It introduces a pay-for-performance element, as payout eligibility and levels are determined based on actual results or performances (such as the Company’s achievement of goals and/or milestones), as well as individual
performance.
|
8.2. |
An annual cash bonus may be awarded to Executive Officers upon the attainment of pre-set periodical objectives and individual targets determined by the
Compensation Committee (and, if required by law, by the Board) at the beginning of each calendar year, or upon engagement, in case of newly hired Executive Officers, taking into account MediWound’s short and long-term goals, as well
as its compliance and risk management policies. The Compensation Committee and the Board shall also determine applicable minimum qualitative or quantitative thresholds that must be met for entitlement to the annual cash bonus (all or
any portion thereof) and the formula for calculating any annual cash bonus payout, with respect to each calendar year, for each Executive Officer. Under special circumstances, as determined by the Compensation Committee and the Board
(e.g., regulatory changes, significant changes in MediWound’s business environment, a significant organizational change, a significant corporate event such as a material strategic commercial transaction, investment/fundraising, an
M&A event, etc.), the Compensation Committee and the Board may modify the objectives and/or their relative weights during the calendar year.
|
8.3. |
In the event the employment of an Executive Officer is terminated prior to the end of a fiscal year, the Company may (but shall not be obligated to) pay such
Executive Officer a full annual cash bonus or a prorated one.
|
8.4. |
The actual annual cash bonus to be awarded to Executive Officers shall be approved by the Compensation Committee and the Board.
|
9. |
Annual Cash Bonuses - The Formula
|
9.1. |
The annual cash bonus of MediWound’s Executive Officers will be based on performance objectives determined by the Compensation Committee (and, if required by
law, by the Board) and/or (to the extent permitted under the Companies Law) a discretionary evaluation by the CEO of the Executive Officer’s (other than the chief executive officer (the "CEO") overall contribution to the Company and/or its affiliates. The performance measurable objectives, which include the objectives and the weight to be assigned to each
achievement in the overall evaluation, may be based on overall company performance measures, such as receipt of regulatory approvals, attainment of milestones, execution of distribution agreements, meeting the Company’s budget, and
financial and operational results, and may further include divisional or personal objectives which may include operational objectives, such as promotion of strategic targets, promotion of innovation, productivity indices, cost
savings, compliance with corporate governance rules and regulatory requirements.
|
9.2. |
The annual cash bonus payable to an Executive Officer for a certain year shall be up to ten (10) months’ of such Executive Officer’s base salary for the
specific year. The Compensation Committee and the Board will set at the beginning of each calendar year the target cash annual bonus.
|
9.3. |
The less significant part of the annual cash bonus granted to MediWound’s CEO, and in any event not more than 25% of the annual cash bonus, may be based on a
discretionary evaluation of the CEO’s overall performance by the Compensation Committee and the Board based on quantitative and qualitative criteria
|
10. |
Special Bonuses
|
11. |
Compensation Recovery (“Clawback”)
|
11.1. |
In the event of an accounting restatement, MediWound shall be entitled to recover from its Executive Officers the bonus compensation or performance-based equity
compensation in the amount in which such compensation exceeded what would have been paid under the financial statements, as restated, provided that a claim is made by MediWound prior to the third anniversary of the fiscal year-end of
the restated financial statements.
|
11.2. |
Notwithstanding the aforesaid, the compensation recovery will not be triggered in the following events:
|
11.2.1. |
The financial restatement is required due to changes in the applicable financial reporting standards; or
|
11.2.2. |
The Compensation Committee has determined that Clawback proceedings in the specific case would be impossible, impractical or not commercially or legally
efficient.
|
11.3. |
Nothing in this Section 11 derogates from any other “Clawback” or similar provisions regarding disgorging of profits imposed on Executive Officers by virtue of
applicable securities laws.
|
12. |
The Objective
|
12.1. |
The equity-based compensation for MediWound’s Executive Officers is designed in a manner consistent with the underlying objectives in determining the base
salary and the annual cash bonus, with its main objectives being to enhance the alignment between the Executive Officers’ interests with the long-term interests of MediWound and its shareholders, and to strengthen the retention and
the motivation of Executive Officers in the long term. In addition, since equity-based awards are structured to vest over several years, their incentive value to recipients is aligned with longer-term strategic plans.
|
12.2. |
The equity-based compensation offered by MediWound is intended to be in a form of share options and/or other equity-based awards, such as RSUs, in accordance
with the Company’s equity incentive plan(s) as may be updated from time to time.
|
12.3. |
All equity-based incentives granted to Executive Officers shall be subject to
vesting periods in order to promote long-term retention of the awarded Executive Officers. Unless determined otherwise in a specific award agreement approved by the Compensation Committee and the Board or unless provided otherwise
in the Company’s equity incentive plan(s), grants to Executive Officers shall vest as follows: 25% of an award shall vest on the first anniversary of the grant date, and 6.25% of the award shall vest at the end of each
subsequent three-month period, provided that the Executive Officer remains continuously employed for that quarter, over the course of the following
three years of continued employment. Performance based incentives shall vest upon the Executive Officer achieving measurable performance objectives. The
exercise price of options shall be determined in accordance with MediWound’s equity incentive plan(s).
|
12.4. |
All other terms of the equity awards shall be in accordance with MediWound’s incentive plans and other related practices and policies. Accordingly, the Board
may, following approval by the Compensation Committee, extend the period of time for which an award is to remain exercisable and make provisions with respect to the acceleration of the vesting period of any Executive Officer’s awards,
including, without limitation, in connection with a corporate transaction involving a change of control, subject to any additional approval as may be required by the Companies Law.
|
13. |
General Guidelines for the Grant of Awards
|
13.1. |
The equity-based compensation shall be granted from time to time and be individually determined and awarded according to the performance, educational
background, prior business experience, qualifications, role and the personal responsibilities of the Executive Officer.
|
13.2. |
In determining the equity-based compensation granted to each Executive Officer, the Compensation Committee and Board shall consider the factors specified in
Section 13.1 above, and in any event the total fair market value of annual equity-based compensation at the time of grant shall not exceed the ratio specified in section 4.2 above.
|
13.3. |
The fair market value of the equity-based compensation for the Executive Officers will be determined according to acceptable valuation practices at the time of
grant.
|
14. |
Advance Notice Period
|
14.1 |
MediWound may provide to an Executive Officer according to his/her
seniority in the Company, his/her contribution to the Company’s goals and achievements and the circumstances of retirement, a prior notice of termination
of: up to six (6) months, during which the Executive Officer
may be entitled to all of the compensation elements, and to the continuation of vesting of his/her equity-based compensation. The foregoing notice
period shall not be available to an Executive Officer that has not served at least one year as an Executive Officer of the Company.
|
14.2 |
During the advance notice period, an Executive Officer will be required to keep performing his/her duties pursuant to his/her agreement with the Company,
unless the Company has waived the Executive Officer’s services to the Company during the advance notice period and paid the amount payable in lieu of notice, plus the value of benefits.
|
15. |
Adjustment Period
|
16. |
Additional Retirement and Termination Benefits
|
17. |
Limitation Retirement and Termination of Service Arrangements
|
18. |
Exculpation
|
19. |
Insurance and Indemnification
|
19.1. |
MediWound may indemnify its directors and Executive Officers, including directors and Executive Officers who are affiliated to MediWound's controlling
shareholder, to the fullest extent permitted by applicable law, for any liability and expense that may be imposed on the director or the Executive Officer, as provided in the indemnity agreement between such individuals and MediWound,
all subject to applicable law and the Company’s articles of association.
|
19.2. |
MediWound will provide directors’ and officers’ liability insurance (the “Insurance Policy”) for its directors and Executive Officers, including directors and Executive Officers who are affiliated to MediWound's controlling shareholder, as follows:
|
19.2.1. |
The annual premium to be paid by MediWound shall not exceed 2% of the aggregate coverage of the Insurance Policy;
|
19.2.2. |
The limit of liability of the insurer (i.e., the insurance coverage), including under a Side A DIC (Difference in Conditions) insurance policy shall not exceed $40 million; and
|
19.2.3. |
The Insurance Policy, as well as the limit of liability and the premium for each extension or renewal shall be approved by the Compensation Committee (and, if
required by law, by the Board) which shall determine that the sums are reasonable considering MediWound’s exposures, the scope of coverage and the market conditions, and that the Insurance Policy reflects the current market
conditions, and it shall not materially affect the Company’s profitability, assets or liabilities.
|
19.3. |
Upon circumstances to be approved by the Compensation Committee (and, if required by law, by the Board), MediWound shall be entitled to enter into a “run off”
Insurance Policy of up to seven (7) years, with the same insurer or any other insurance, as follows:
|
19.3.1. |
The limit of liability of the insurer shall not exceed $40 million;
|
19.3.2. |
The premium for the run-off period shall not exceed 300% of the last paid annual premium; and
|
19.3.3. |
The Insurance Policy, as well as the limit of liability and the premium for each extension or renewal shall be approved by the Compensation Committee (and, if
required by law, by the Board) which shall determine that the sums are reasonable considering the Company’s exposures covered under such policy, the scope of cover and the market conditions, and that the Insurance Policy reflects the
current market conditions and that it shall not materially affect the Company’s profitability, assets or liabilities.
|
19.4. |
MediWound may extend the Insurance Policy in place to include cover for
liability pursuant to a future public offering of securities as follows:
|
19.4.1. |
The additional premium for such extension of liability coverage shall not exceed 30% of the last paid annual premium; and
|
19.4.2. |
The Insurance Policy, as well as the additional premium shall be approved by the Compensation Committee (and if required by law, by the Board) which shall
determine that the sums are reasonable considering the exposures pursuant to such public offering of securities, the scope of cover and the market conditions and that the Insurance Policy reflects the current market conditions, and it
does not materially affect the Company’s profitability, assets or liabilities.
|
20. |
The following compensation shall be paid to MediWound's Board members:
|
20.1. |
All of MediWound’s non-employee Board members shall be entitled to annual and per-meeting compensation. Alternatively, MediWound’s Board members may receive only an annual payment with respect to their
services on the Board and additional annual payments for serving on Board committees and as chairperson of the Board or its committees, without regard to their participation in meetings of the Board or its committees. A Board
member’s annual cash fee (per calendar year) shall not exceed $150,000 plus VAT.
|
20.2. |
The compensation of the Company’s external directors, if elected, shall be in accordance with the Companies Law Regulations (Rules Regarding the Compensation
and Expenses of an External Director), 5760-2000, as amended by the Companies Regulations (Relief for Public Companies Traded in Stock Exchange Outside of Israel), 5760-2000, as such regulations may be amended from time to time,
including the “relative compensation” track for external directors provided under those regulations.
|
20.3. |
Notwithstanding the provisions of Sections 20.1 and 20.2 above, in special circumstances, such as in the case of a professional director, an expert director or
a director who makes a unique contribution to the Company, such director’s compensation may be different than the compensation of all other directors and may be greater than the maximal amount allowed under Section 20.1 and/or the
amount prescribed under Section 20.2.
|
20.4. |
Each non-employee member of MediWound’s Board, may be granted annual
equity-based compensation. The maximum equity award annual compensation value on the date of grant for each equity-based compensation shall preserve
the ration between the fixed component and the variable component, as set forth in section 4.2.
|
20.5. |
Unless provided otherwise with respect to a specific grant, annual equity-based compensation granted to a non-employee member of the Board shall generally vest
and become exercisable in three equal annual installments on the first, second and third anniversaries of the grant date, and shall have a term expiring five years from the date of grant, unless earlier terminated in accordance with
MediWound’s equity incentive plan(s).
|
20.6. |
All other terms of the equity awards shall be in accordance with MediWound’s incentive plans and other related practices and policies. Accordingly, the Board
may, following approval by the Compensation Committee, extend the period of time for which an award is to remain exercisable and make provisions with respect to the acceleration of the vesting period of any awards, including, without
limitation, in connection with a corporate transaction involving a change of control, subject to any additional approval as may be required by the Companies Law.
|
20.7. |
In addition, members of MediWound’s Board may be entitled to reimbursement of expenses in connection with the performance of their duties.
|
20.8. |
It is hereby clarified that the compensation (and limitations) stated under Section G will not apply to directors who serve as Executive Officers.
|
21. |
Nothing in this Policy shall be deemed to grant any of MediWound’s Executive
Officers or employees or any third party any right or privilege in connection with their employment by the Company. Such rights and privileges shall be governed by the respective personal employment agreements. The Board may
determine that none or only part of the payments, benefits and perquisites detailed in this Policy shall be granted, and is authorized to cancel or suspend a compensation package or part of it.
|
22. |
This Policy is subject to applicable law and is not intended, and should not be interpreted as limiting or derogating from, provisions of applicable law to the
extent not permitted, nor should it be interpreted as limiting or derogating from the Company’s Articles of Association. This Policy is not intended to affect current agreements nor affect obligating customs (if applicable) between
the Company and its Executive Officers as such may exist prior to the approval of this Compensation Policy, subject to any applicable law.
|
23. |
In the event that new regulations or law amendment in connection with Executive Officers’ and directors’ compensation will be enacted following the adoption of this Policy, MediWound may follow such new regulations or law amendments, even if such new regulations are in contradiction to the compensation
terms set forth herein.
|
1.
|
Capitalized terms not defined herein shall have the meaning ascribed to them in the Amended and Restated Articles of
Association of MediWound Ltd. (the “Company”), which were adopted by the Company effective as of March 25, 2014 (the “Articles”).
|
1.
|
Article 6 of the Articles is hereby amended in its entirely to state as follows:
|
■ 00032030000000000000 9
|
092619
|
Directions (Item 1A)
PLEASE BE CERTAIN TO FILL IN THE BOX “FOR” ITEM 1A OPPOSITE TO CONFIRM THAT YOU ARE NOT A CONTROLLING SHAREHOLDER
AND DO NOT HAVE A CONFLICT OF INTEREST (REFERRED TO AS A “PERSONAL INTEREST” UNDER THE ISRAELI COMPANIES LAW) IN THE APPROVAL OF PROPOSAL 1.
If you believe that you, or a related party of yours, has such a conflict of interest, or if you are a controlling shareholder, and you wish to
participate in the vote on Proposal 1, you should check the box “AGAINST” Item 1A. In that case, your vote will count towards or against the ordinary majority required for the approval of Proposal 1, but will not count towards or against
the special majority required for the approval of Proposal 1.
IF YOU DO NOT INDICATE WHETHER OR NOT YOU ARE A CONTROLLING SHAREHOLDER AND/OR HAVE A CONFLICT OF INTEREST IN ITEM 1A, YOUR VOTE
WILL NOT BE COUNTED AT ALL FOR PROPOSAL 1.
|
FOR
|
AGAINST
|
ABSTAIN
|
||
1. Approval of an updated compensation policy for the executive officers and directors of the Company.
|
☐
|
☐
|
☐
|
||
1A. The undersigned hereby confirms that he, she or it is not a controlling shareholder and does not have a conflict of interest in the approval
of Proposal 1. [MUST COMPLETE]
|
☐
|
☐
|
|||
2. Approval of an amendment to Article 6 of the Company’s articles of association to increase the Company’s authorized share capital by
12,755,492 ordinary shares, to 50,000,000 ordinary shares.
|
☐
|
☐
|
☐
|
||
|
|||||
To change the address on your account, please check the box at the right and indicate your new address in the space above. Please note that changes to the registered name(s) on the account may not be submitted via this method. | ☐ |
Signature of shareholder
|
Date:
|
Signature of shareholder
|
Date:
|
Note: |
Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each owner should sign. When signing as executor, administrator, attorney, trustee or guardian, please give full title as such. If the
signer is a corporation, please sign full corporate name by a duly authorized officer, giving full title as such. If the signer is a partnership, please sign in partnership name by authorized person.
|